Treatment with anti-ErbB2 antibodies

A method for the treatment of a human patient diagnosed with a disorder characterized by overexpression of ErbB2 receptor, comprising administering an effective amount of a combination of an anti-ErbB2 antibody and a chemotherapeutic agent selected from the group consisting of alkylating agents such as thiotepa and cyclosphosphamide;

• alkyl sulfonates such as busulfan, improsulfan and piposulfan;
• aziridines such as benzodopa, carboquone, meturedopa, and uredopa;
• ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine;
• nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard;
• nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;
• antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L-norleucine, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin;
• anti-metabolites such as methotrexate and 5-fluorouracil (5-FU);
• folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate;
• purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;
• pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU;
• androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone;
• anti-adrenals such as aminoglutethimide, mitotane, trilostane;
• folic acid replenisher such as frolinic acid;
• aceglatone;
• aldophosphamide glycoside;
• aminolevulinic acid;
• amsacrine;
• bestrabucil;
• bisantrene;
• edatraxate;
• defofamine;
• demecolcine;
• diaziquone;
• elfomithine;
• elliptinium acetate;
• etoglucid;
• gallium nitrate;
• hydroxyurea;
• lentinan;
• lonidamine;
• mitoguazone;
• mitoxantrone;
• mopidamol;
• nitracrine;
• pentostatin;
• phenamet;
• pirarubicin;
• podophyllinic acid;
• 2-ethylhydrazide;
• procarbazine;
• PSK®;
• razoxane;
• sizofiran;
• spirogermanium;
• tenuazonic acid;
• triaziquone;
• 2, 2′,2″-trichlorotriethylamine;
• urethan;
• vindesine;
• dacarbazine;
• mannomustine;
• mitobronitol;
• mitolactol;
• pipobroman;
• gacytosine;
• arabinoside (“Ara-C”);
• cyclophosphamide;
• thiotepa;
• taxoids such as paclitaxel and docetaxel;
• chlorambucil;
• gemcitabine;
• 6-thioguanine;
• mercaptopurine;
• methotrexate;
• platinum analogs such as cisplatin and carboplatin;
• vinblastine;
• platinum;
• etoposide (VP-16);
• ifosfamide;
• mitomycin C;
• mitoxantrone;
• vincristine;
• vinorelbine;
• navelbine;
• novantrone;
• teniposide;
• daunomycin;
• carminomycin;
• aminopterin;
• xeloda;
• ibandronate;
• CPT-11;
• topoisomerase inhibitor RFS 2000;
• difluoromethylomithine (DMFO);
• retinoic acid;
• esperamicins;
• capecitabine;
• hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone;
• and anti-androgens such as flutamide and nilutamide;
• and pharmaceutically acceptable salts, acids or derivatives of any of the above, in the absence of an anthracycline derivative, to the human patient.